ES2575218T3 - Método de tratamiento de enfermedades neurodegenerativas o neuromusculares degenerativas y agente terapéutico para tratar las mismas - Google Patents

Método de tratamiento de enfermedades neurodegenerativas o neuromusculares degenerativas y agente terapéutico para tratar las mismas Download PDF

Info

Publication number
ES2575218T3
ES2575218T3 ES10813434.7T ES10813434T ES2575218T3 ES 2575218 T3 ES2575218 T3 ES 2575218T3 ES 10813434 T ES10813434 T ES 10813434T ES 2575218 T3 ES2575218 T3 ES 2575218T3
Authority
ES
Spain
Prior art keywords
component
treatment
treat
therapeutic agent
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10813434.7T
Other languages
English (en)
Inventor
Munisekhar Medasani
Satyasayee Babu Divi
Satya Laxmi Priyanka Palempati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2575218T3 publication Critical patent/ES2575218T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición terapéutica sinérgica para uso en la prevención, eliminación, tratamiento y control de trastornos y enfermedades neurodegenerativos y neuromusculares degenerativos en sujetos humanos y animales, tales como esclerosis lateral amiotrófica (ELA), esclerosis múltiple (EM), enfermedad de Alzheimer (EA), enfermedad de Parkinson (EP), y distrofia muscular (DM) y otras, que comprende un primer componente y un segundo componente, siendo dicho primer componente D-manitol, y siendo dicho segundo componente ácido ascórbico en cualquiera de las formas seleccionadas entre la forma oxidada, la forma reducida, los ascorbatos minerales, los ésteres de ácidos grasos del ácido ascórbico, vitamina C o DHA, o cualquiera de las mezclas de dichas formas.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
5
10
15
20
25
30
35
40
45
50
Referencias:
1.
The Influence of Mannitol on Myoglobinuric Acute Renal Failure: Functional, Biochemical, and Morphological Assessments 1 Richard A. Zager, 2 Charles Foerder, and Charles Bredl (J. Am. Soc. Nephrol. 1991; 2:848-855).
2.
The Early Response of Mannitol Infusion in Traumatic Brain Injury Kao-Chang Lin1, Chih-Ho Chou1, Wei-Lung Chang1, Der-Shin Kel and Jinn-Rung Kuo2 (Acta Neurol Taiwan 2008; 17:26-32) (Acta Neurologica Taiwanica Vol 17 No 1 March 2008).
3.
Mannitol, Furosemide, and Dopamine Infusion in Postoperative Renal Failure Complicating Cardiac Surgery Srikrishna Sirivella, MD, Isaac Gielchinsky, MD, and Victor Parsonnet, MD Department of Cardiovascular and Thoracic Surgery, Newark Beth Israel Medical Center, Newark, New Jersey (SIRIVELLA ET AL Ann Thorac Surg MANNITOL INFUSION IN ACUTE RENAL FAILURE 2000; 69:501-6).
4.
Effect of Mannitol on serum and Urine Electrolyte in Neurosurgical patients. Jong Hoon Kim, M.D., Kabsu Kim, M.D., and Yong Tack Nam, M.D. and Kwang Won Park, M.D. Department of Anesthesiology, Yonsei University College of Medicie, seoul, Korea. The Journal of the Korean society of Anesthesiologists: V1.25, No. 3, 1992
5.
Zinc Deficiency in the Rat: Effect on serum and intestinal alkaline phosphatase activities1'2 RICHARD W. LUECKE, MARY E. OLMAN AND BETTY V. BALTZER Department of Biochemistry, Michigan State University, East Lansing, Michigan (J. NUTRITION, 94: '68.)
6.
Lowry, O. H., N. R. Roberts, M-L. Wu, W. H. Hixon and E. J. Crawford 1954 The quantitative histochemistry of brain. II. Enzyme measurements. J. Biol. Chem., 207:
7.
Zinc Deficiency Exacerbates loss in Blood-Brain Barrier Integrity Induced by Hyperoxia Measured by Dynamic MRI (4477). Michael D. Noseworthy and Tammy M. Bray. Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada NIG 2W1; and Department of Human Nutrition, The Ohio state University, Columbus, Ohio 43210-1295. (P.S.E.B.M. 2000, vol 223).
8.
Effect of Zinc on Lipid Peroxidation and Metal content in some Tissues of Rats. MILOS CHVAPIL, YEIMEI PENG ARTHUR L. ARONSON and CHARLES ZUKOSKI. Division of surgical Biology, Department of surgery, University of Arizona, College of Medicine, Tucson, Arizona 85724. Jn. nutrition.org by on Aug. 7, 2009.
9.
Effect of Dietary Zinc on Endogenous Free Radical production in rat Lung Microsomes. TAMMY M. BRAY, STAN KUBOW and WILLIAM BETTGER.Department of Nutrition, college of Biological Science, University of Guelph, Ontario, Canada N1G 2W1. Jn. nutrition.org Aug. 7, 2009.
10.
Antioxidant-Like Properties of Zinc in Activated Endothelial Cells. Bernhard Hennig, PhD, FACN, Purushothaman Meerarani, PhD, Michel Toborek, MD, PhD, FACN and Craig J. McClain, MD, FACN Departments of Nutrition and Food Science (B.H., P.M.), Neurosurgery (M.T.), and Medicine (C.J.M.), University of Kentucky, Lexington, Kentucky.
11.
Copper-and Zinc-containing Super oxide Dismutase Can Act as a Superoxide Reductase and a Superoxide Oxidase*. Stefan I. Liochev and Irwin Fridovich. From the Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710. THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 275, No. 49, Issue of December 8, pp. 38482-38485, 2000
12.
Essential role of Ascorbic acid Neural differentiation and Development: High levels of ascorbic acid 2-glucoside effectively enhance nerve growth factor-induced neurite formation and elongation in PC12 cells (journal of health science: 54(1) 43-49 (2008).)
13.
Efficacy of Dietary Antioxidants to Prevent Oxidative Damage and Inhibit Chronic Disease1,2 Balz Frei, Linus Pauling Institute, Oregon State University, Corvallis OR 97331-6512 (J. Nutr. 134:3196S-3198S, November 2004).
14.
Free Radicals and Oxidative Stress in Neurodegenerative Diseases: Relevance of Dietary Antioxidants. Ravindra Pratap Singh, Shashwat Sharad, Suman Kapur (JIACM 2004; 5(3): 218-25).
15.
Myenteric neurons and intestinal mucosa of diabetic rats after ascorbic acid supplementation. Priscila de Freitas, Maria Raquel Marçal Natali, Renata Virginia Fernandes Pereira, Marcilio Hubner Miranda Neto, Jacqueline Nelisis Zanoni. (World J Gastroenterol 2008 Nov. 14; 14(42): 6518-6524, World Journal of Gastroenterology ISSN 10079327, ©2008 The WJG Press. All rights reserved.).
16.
OXIDATIVE STRESS IN PARKINSON'S DISEASE Shashikant Nikam, Padmaja Nikam, S K Ahaley and Ajit V Sontakke Department of Biochemistry, Government Medical College, Miraj and KIMS, Karad Maharashtra, India (Indian Journal of Clinical Biochemistry, 2009/24 (1) 98-101).
17.
Kontush A, Mann U, Arlt S, Ujeyl A, Luhrs C, Muller-Thomsen T, Beisiegel U. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. (Free Radic Biol Med. 2001; 31:345354.).
8
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10813434.7T 2009-09-04 2010-09-02 Método de tratamiento de enfermedades neurodegenerativas o neuromusculares degenerativas y agente terapéutico para tratar las mismas Active ES2575218T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2149CH2009 2009-09-04
INCH21492009 2009-09-04
PCT/IN2010/000583 WO2011027363A2 (en) 2009-09-04 2010-09-02 Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same

Publications (1)

Publication Number Publication Date
ES2575218T3 true ES2575218T3 (es) 2016-06-27

Family

ID=43649728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10813434.7T Active ES2575218T3 (es) 2009-09-04 2010-09-02 Método de tratamiento de enfermedades neurodegenerativas o neuromusculares degenerativas y agente terapéutico para tratar las mismas

Country Status (11)

Country Link
US (1) US8962039B2 (es)
EP (1) EP2473037B1 (es)
JP (2) JP2013503853A (es)
KR (1) KR20120046795A (es)
CN (1) CN102497778A (es)
AU (1) AU2010290795B2 (es)
CA (1) CA2772191A1 (es)
ES (1) ES2575218T3 (es)
NZ (1) NZ599082A (es)
SG (2) SG178942A1 (es)
WO (1) WO2011027363A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599082A (en) * 2009-09-04 2014-06-27 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
KR101423005B1 (ko) * 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
CN103739578B (zh) * 2013-12-20 2016-07-13 李玉成 柠檬酸氢抗坏血酸锌及其制备方法和应用
WO2018039526A1 (en) * 2016-08-25 2018-03-01 Wright State University Treatment of neurodegenerative disorders and pain
CN111511358A (zh) * 2017-12-26 2020-08-07 花王株式会社 认知功能改善剂
WO2020101181A1 (ko) * 2018-11-14 2020-05-22 주식회사 넥스모스 압타머를 유효성분으로 포함하는 퇴행성 뇌질환 치료 및 예방용 조성물
CN109662960A (zh) * 2018-12-14 2019-04-23 华中科技大学 甘露醇在制备用于治疗阿尔茨海默病的药物中的应用以及药物组合物
JP7506903B2 (ja) * 2019-11-01 2024-06-27 日本メナード化粧品株式会社 Ｉｌ－３７産生促進剤
KR102293111B1 (ko) * 2019-11-26 2021-08-25 (주)큐엘바이오 오미자 추출물 및 아스코르브산 혼합물을 유효성분으로 함유하는 인지기능, 기억력 및 활동성 증진용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624628D0 (en) * 1986-10-14 1986-11-19 Scras Soluble/splitable tablets
US4956391A (en) * 1988-08-17 1990-09-11 Sapse Alfred T Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US7582786B2 (en) * 1992-12-07 2009-09-01 Eukarion Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
ATE318599T1 (de) * 2000-12-22 2006-03-15 Astellas Pharma Inc Famotidin-injektionen
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2006527987A (ja) * 2003-07-21 2006-12-14 ユニリーバー・ナームローゼ・ベンノートシヤープ 認識機能の補助
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
US20100098752A1 (en) * 2007-01-18 2010-04-22 Pinsky Mark A Materials and Methods for Delivering Antioxidants into the Skin
KR100815277B1 (ko) * 2007-04-27 2008-03-19 주식회사 케이티앤지 홍삼 산성다당체 및 구기자추출물을 함유하는 항고지혈증제
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
EP2262512A1 (en) * 2008-02-28 2010-12-22 Henry Ford Health System Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries
NZ599082A (en) * 2009-09-04 2014-06-27 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same

Also Published As

Publication number Publication date
NZ599082A (en) 2014-06-27
EP2473037A2 (en) 2012-07-11
JP2013503853A (ja) 2013-02-04
WO2011027363A3 (en) 2011-06-30
JP6157572B2 (ja) 2017-07-05
US20120164245A1 (en) 2012-06-28
AU2010290795A1 (en) 2012-04-19
JP2016074708A (ja) 2016-05-12
EP2473037A4 (en) 2013-05-08
AU2010290795B2 (en) 2015-12-10
SG178942A1 (en) 2012-04-27
SG10201405392RA (en) 2014-10-30
CN102497778A (zh) 2012-06-13
EP2473037B1 (en) 2016-03-09
KR20120046795A (ko) 2012-05-10
WO2011027363A2 (en) 2011-03-10
CA2772191A1 (en) 2011-03-10
US8962039B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
ES2575218T3 (es) Método de tratamiento de enfermedades neurodegenerativas o neuromusculares degenerativas y agente terapéutico para tratar las mismas
Godoy et al. Quercetin exerts differential neuroprotective effects against H 2 O 2 and Aβ aggregates in hippocampal neurons: the role of mitochondria
ES2600909T3 (es) Composiciones que contienen berberina o análogos de la misma para tratar rosácea o trastornos de la piel relacionados con enrojecimiento de la cara
Erdő et al. Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review
Yuan et al. Curcumin attenuates blood-brain barrier disruption after subarachnoid hemorrhage in mice
Pischon et al. Stratum corneum targeting by dendritic core-multishell-nanocarriers in a mouse model of psoriasis
Miyaoka et al. Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases in patients with psychiatric disorders
Glantz et al. Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia
AU2008261901A1 (en) Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof
Sazegar et al. The effects of supplemental zinc and honey on wound healing in rats
KR20180098695A (ko) 지방 감소를 위한 담즙산 및 염의 방법 및 조성물
Kim et al. Synergistic enhancement of skin permeability by N-lauroylsarcosine and ethanol
Pujari et al. Oxidants and antioxidant status in psoriasis patients
WO2003024446A1 (fr) Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif
Agren Influence of two vehicles for zinc oxide on zinc absorption through intact skin and wounds.
Li et al. NIR-II fluorescence imaging of skin avulsion and necrosis
Huo et al. Delayed diagnosis of glucagonoma syndrome: a case report.
KOCJAN et al. HERBAL PREPARATION EXTRACT FOR SKIN AFTER RADIOTHERAPY TREATMENT. PART ONE ñ PRECLINICAL TESTS
US20230381220A1 (en) Pegylated menaquinol compositions and methods of treatment
Baweja et al. Oxidant and antioxidant status in patients with psoriasis
US20220233696A1 (en) Topical formulations containing phthalocyanine photosensitizers
Abbas et al. Assessment of serum and salivary malondialdehyde in patients with oral lichen planus
Andreu-Barasoain et al. Intravesical mitomycin C–induced generalized pustular folliculitis
Baniasadi Rad et al. Effects of Simvastatin on Gentamicin-induced kidney injury in rats
Schlotmann et al. Placebo‐controlled evaluation of the irritant potential of tacalcitol (1α, 24‐dihydroxyvitamin D3) in healthy volunteers